IBL Finance is a technology-driven non-banking financial company that provides small-ticket instant personal loans to individuals via a mobile app and wholesale term loans to other financial institutions.
The company lacks a durable moat as its primary products are small-ticket unsecured personal loans and wholesale lending to other NBFCs, both of which are highly commoditized. While they claim a technology edge, the low average ROCE of 6% and high Net NPA levels relative to profit suggest no significant pricing power or cost advantage over competitors.
Management has focused on rapid AUM expansion, growing from 15 crore to 114 crore in three years, primarily funded by new debt and IPO proceeds. However, this growth has not yet translated into high returns on capital, with ROE remaining stagnant around 4%.
The aggressive AUM expansion proved to be a house of cards as the unsecured personal loan book deteriorated during a credit downcycle. The company's thin interest coverage of 1.5x left no room for error, and the negative cash conversion finally caught up with the balance sheet, leading to a liquidity crunch. As defaults rose, the lack of a cost advantage or proprietary technology became evident, and the capital previously diverted to related parties was unavailable to cushion the blow, resulting in a permanent impairment of equity.
RichFakir rates IBL Finance Ltd's business quality as poor — 21/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, IBL Finance Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on IBL Finance Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of IBL Finance Ltd's fair value is about ₹11 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →